First Tracks Biotherapeutics TRAX

NASDAQ TRAX
$46.56 -0.54 (-1.15%)
At close: Nov 16, 2026 · 4:00 PM EST

First Tracks Biotherapeutics (TRAX) stock price is $46.56, down 1.15% on the day, as of Nov 16, 2026. It has a market cap of $1.66Bn, and is classified in the Biotechnology industry (Healthcare sector).

Key Stats
Market Cap1.66 Bn
P/E-5.91
FCF (Yr)-142.84 Mn
ROA (Yr)-43.09
EV to EBIT-2.47
Net Income (Yr)-166.09 Mn
Enterprise Value740.14 Mn
Add ratio to table…

About

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's core activities involve the discovery and development of monoclonal antibodies targeting key immune pathways, with a pipeline comprising three investigational candidates: rosnilimab for rheumatoid arthritis, ANB033 for celiac disease and eosinophilic esophagitis, and ANB101 for systemic…

Read more ↓
Sector: Healthcare Sector rationale First Tracks Biotherapeutics is a clinical-stage biotechnology company developing monoclonal antibodies (rosnilimab, ANB033, and ANB101) for autoimmune and inflammatory diseases. Its core business is the discovery and development of medical therapeutics, which falls squarely within the Biotechnology industry of the Healthcare sector. Industry: Biotechnology Biotechnology Primary First Tracks Biotherapeutics is a clinical-stage biotechnology company developing monoclonal antibodies, such as rosnilimab and ANB033, which are therapies derived from biological science. Its business model focuses on the research and development of these biologics for autoimmune and inflammatory diseases. Classified using BQ-MICS CIK: 0002091349
Peer percentiles

How First Tracks Biotherapeutics ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −5.99xMedian 17.0x 60th
  • P/FCFNegative free cash flow −15.4xMedian 19.0x 71st
  • P/Operating cash flowNegative operating cash flow −15.4xMedian 16.4x 71st
  • P/S —Median 8.38x No data —
  • P/B 11.2xMedian 2.04x 10th
  • P/Tangible book 11.2xMedian 2.31x 11th
  • EV/EBITDANegative EBITDA −5.13xMedian 14.6x 52nd
  • EV/EBITNegative EBIT −5.12xMedian 18.4x 54th
  • EV/Revenue —Median 6.34x No data —
  • EV/FCFNegative free cash flow −14.0xMedian 23.4x 65th
  • EV/Operating cash flowNegative operating cash flow −13.9xMedian 19.3x 65th
  • PEG (3Y EPS CAGR) —Median 0.43 No data —
Peer group

Peer Comparison

Companies in the Biotechnology
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,276.89 Bn46.3014.7749.50 Bn
2 JNJ Johnson & Johnson 681.31 Bn42.336.8644.65 Bn
3 ABBV AbbVie Inc. 520.63 Bn50.347.8980.90 Bn
4 MRK Merck & Co., Inc. 357.22 Bn145.635.3053.78 Bn
5 NVS Novartis Ag 310.90 Bn17.915.08-
6 AZN Astrazeneca Plc 285.12 Bn25.854.80-5.53 Bn
7 AMGN Amgen Inc 250.23 Bn26.656.4354.01 Bn
8 TRAX First Tracks Biotherapeutics, Inc. 1.66 Bn-5.91--